Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)-Reference-Cited by-同舟云学术

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Published:2016-12 Issue:12 Volume:27 Page:2236-2241
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Sehouli J.,Chekerov R.,Reinthaller A.,Richter R.,Gonzalez-Martin A.,Harter P.,Woopen H.,Petru E.,Hanker L.C.,Keil E.,Wimberger P.,Klare P.,Kurzeder C.,Hilpert F.,Belau A.K.,Zeimet A.,Bover-Barcelo I.,Canzler U.,Mahner S.,Meier W.

Funder

GlaxoSmithKline and AMGEN

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/12/2236/8623033/mdw418.pdf

Reference19 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J Clin Oncol Off J Am Soc Clin Oncol,1991

3. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;Gynecol Oncol,1990